Miyata

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Retrieved on: 
Thursday, September 29, 2022
Medical Supplies, Biotechnology, Technology, Health, Optical, Robotics, Health Technology, Medical Devices, Surgery, Audio, Video, Hardware, Adult, ROI, American Academy, Contraindication, Aphakia, ARGOS, Lists of diseases, Patient, Physician, Irritation, Bleeding, Central Time, Glaucoma, Eye, User, SMS, Cornea, Student, Visual acuity, Approximation error, Direction, Glasses, Surgeon, American Academy of Ophthalmology, Virtual reality, NYSE, Risk, ORA, News, Diabetes, Presbyopia, Region, Disorder, Light, AAO, SS, Eyelid, Incidence, Intraocular lens, Fidelis, Astigmatism, Retina, Maintenance, Patient satisfaction, Cataract, Life: A User's Manual, Quality of life, Use, Solution, Family, Red, Vision system, Iris, Swelling, Miyata, Telescopic sight, Medical imaging, Dentistry, Medicine, Alcon, IOL, Ophthalmology

Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.

Key Points: 
  • Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.
  • These activities will take place at Alcon booth #3926 at the AAO exhibit hall, on Oct. 1-3 from 9:00 a.m.5:00 p.m. Central Time.
  • The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.

Sensome Raises $9 Million B Round With Equity Investment From ASAHI INTECC

Retrieved on: 
Monday, January 13, 2020
Health, Surgery, Cardiology, Medical devices, Asahi, Miyata, Stroke, Economy of Japan

The funds raised will serve to test the clinical performance of Sensomes first product Clotild, aproprietary connected guidewire, and get it ready for market.

Key Points: 
  • The funds raised will serve to test the clinical performance of Sensomes first product Clotild, aproprietary connected guidewire, and get it ready for market.
  • Sensome and Asahi also agreed to a two-year development plan to design a new connected guidewire for the treatment of ischemic stroke, combining Sensomes proprietary micro-sensor and Asahis CHIKAI guidewire.
  • An easy-to-use high-performance guidewire with onboard sensor will allow the physician to know more about the clot without significant disruption to the current procedure, explained Masahiko Miyata, CEO of Asahi Intecc.
  • Asahi is confident that this collaboration will yield a revolutionary smart guidewire with excellent mechanical performance and unique capability.